PTX3 and COVID-19: A meta-analysis identified PTX3 as a reliable marker for poor outcomes following COVID-19 infection (121), and it was found to be a useful clinical biomarker for predicting the 30-day risk of respiratory failure and mortality in COVID-19 patients, regardless of remdesivir or dexamethasone treatment (122).